NDA 202008 · Avid Radiopharms INC
Amyvid
Florbetapir F-18 · Intravenous · Radioactive Diagnostic Agent
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jun 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Apr 6, 2012
Approved uses
2
Original approval plus efficacy supplements
Registered trials
59
7 Phase 3, 6 recruiting
FAERS reports
115
23 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 11, 2025.
AMYVID is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products AMYVID is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products ( 1 )
Mechanism: Florbetapir F 18 binds to amyloid beta plaques and the F 18 isotope produces a positron signal that is detected by a PET scanner. In in vitro binding studies using postmortem human brain homogenates containing amyloid beta plaques, the dissociation constant (Kd) for florbetapir was 3.7 ± 0.3 nM. The binding of florbetapir F 18 to amyloid beta aggregates was demonstrated in postmortem human brain sections using autoradiographic methods, thioflavin S and traditional silver staining correlation studies as well as immunohistochemistry (monoclonal antibody to amyloid beta) correlation studies....
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 23, 2025 Supplement 46 · Efficacy LabelLetter
- Apr 6, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewLabelLetter
4 products under this application
- AMYVID · FLORBETAPIR F-18 10-50ML (13.5-51mCi/ML) · SOLUTION, INTRAVENOUS · Prescription
- AMYVID · FLORBETAPIR F-18 10ML (13.5-51mCi/ML) · SOLUTION, INTRAVENOUS · Discontinued
- AMYVID · FLORBETAPIR F-18 10-100ML (13.5-51mCi/ML) · SOLUTION, INTRAVENOUS · Prescription
- AMYVID · FLORBETAPIR F-18 10-30ML (13.5-51mCi/ML) · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Florbetapir F-18" as an intervention, any sponsor and status, largest first.
Avid RadiopharmaceuticalsIndustry
NCT01518374 · 1,768 participants · Start Dec 2009 · Primary completion May 3, 2017
Drug: Florbetapir F 18 · For: Alzheimer Disease; Mild Cognitive Impairment; Neurodegenerative Diseases
Sites: Phoenix, Arizona; Sun City, Arizona; Davis, California · 26 sites in all
- Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive DeclinePivotal-lookingCompleted
Avid RadiopharmaceuticalsIndustry
NCT01703702 · 641 participants · Start Oct 2012 · Primary completion Apr 2015
Drug: florbetapir (18F) · For: Alzheimer's Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Sun City, Arizona · 57 sites in all
- Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD SubjectsPivotal-lookingCompleted
Avid RadiopharmaceuticalsIndustry
NCT02016560 · 383 participants · Start Dec 2013 · Primary completion Jul 28, 2017
Drug: florbetapir F 18; Flortaucipir F18 · For: Alzheimer's Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Sun City, Arizona · 27 sites in all
- Biomarker Exploration in Aging, Cognition and NeurodegenerationPivotal-lookingRecruiting
University of California, IrvineAcademic, hospital or other
NCT03860857 · 300 participants (planned) · Start May 1, 2018 · Primary completion Dec 22, 2026
Drug: Tau PET scan using MK-6240 · For: Alzheimer Disease; Cognitive Impairment; Cognitive Decline
Sites: Irvine, California
- Modeling the Relationships Between Functional Connectivity and Amyloid Deposition in Alzheimer's DiseaseStatus unknown
Chang Gung Memorial HospitalAcademic, hospital or other
NCT04174287 · 300 participants (planned) · Start Mar 28, 2019 · Primary completion Mar 27, 2023
Drug: F-18-AV45 · For: Alzheimer's Disease
Sites: Taoyuan City, Taiwan
Avid RadiopharmaceuticalsIndustry
NCT02051790 · 241 participants · Start Mar 2014 · Primary completion Aug 2014
Drug: florbetapir F 18 · For: Alzheimer's Disease
Sites: Philadelphia, Pennsylvania
- Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension StudyRecruiting
Institut National de la Santé Et de la Recherche Médicale, FranceGovernment (non-federal)
NCT05806697 · 240 participants (planned) · Start Apr 14, 2023 · Primary completion Oct 9, 2030
Drug: Blood sampling; Lumbar puncture · For: Alzheimer Disease; Memory Complaint; Memory Disorders
Sites: Paris, France
- Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive DeclinePivotal-lookingCompleted
Avid RadiopharmaceuticalsIndustry
NCT01400425 · 239 participants · Start Jul 2011 · Primary completion Jul 2012
Drug: florbetapir F 18 · For: Progressive Cognitive Decline
Sites: Phoenix, Arizona; Sun City, Arizona; San Francisco, California · 18 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- amyloid related imaging abnormality-oedema/effusion28
- amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits27
- headache14
- superficial siderosis of central nervous system9
- injection site pain7
- chest pain4
- fall4
- fatigue4
- nausea4
- balance disorder3
- burning sensation3
- confusional state3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 15 |
| 2016 | 7 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 45 |
| 2024 | 6 |
| 2025 | 18 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease.
Salloway S, Pain A, Lee E, et al. · Alzheimers Dement 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals.
Sperling RA, Johnson KA, Doraiswamy PM, et al. · Neurobiol Aging 2013 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- A high-glycemic diet is associated with cerebral amyloid burden in cognitively normal older adults.
Taylor MK, Sullivan DK, Swerdlow RH, et al. · Am J Clin Nutr 2017 · Randomized Controlled Trial
- Physical Activity and Amyloid-β Brain Levels in Elderly Adults with Intact Cognition and Mild Cognitive Impairment.
de Souto Barreto P, Andrieu S, Payoux P, et al. · J Am Geriatr Soc 2015 · Multicenter Study, Randomized Controlled Trial
- Tau PET probes for Alzheimer's disease detection and their structural characterization.
Chinnathambi S, Malik S, Chandrashekar M · Adv Protein Chem Struct Biol 2025 · Systematic Review, Research Support, N.I.H., Extramural
- Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.
Johnson KA, Sperling RA, Gidicsin CM, et al. · Alzheimers Dement 2013 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Avid Radiopharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.